Development of Patient Stratification Technologies and Customized Interventions to Achieve Optimal Program Outcomes
This article features preliminary findings from a cardiovascular disease management program recently implemented as a collaborative effort between WellPoint Health Networks® (WellPoint) and Pfizer Health Solutions Inc. (PHS). Beginning in late 1999 and continuing into 2001, WellPoint and PHS have partnered in this program to deliver a secondary risk reduction program to members of Blue Cross of California.
WellPoint provides healthcare to more than 7.6 million medical members and 34 million specialty members nationwide. In California, care is provided through Blue Cross of California, and outside of California by UNICARE. The company offers a broad product line, with open access preferred-provider organization, point-of-service and hybrid products, as well as health-maintenance organization and specialty products. PHS is a subsidiary of Pfizer Inc., and was formed in 1995 to help enhance patient-provider interactions through adoption of new business practices and leading technologies. PHS customers include more than 80 managed-care organizations, hospitals, integrated delivery systems and medical groups.
KeywordsDisease Management Program Behavioral Risk Factor Surveillance Survey Nurse Care Manager Current Health Behavior Blood Thinner
- 1.Extending the coronary artery disease (CAD) economic model: a return on investment analysis for Pfizer Health Solutions: the effect of increased compliance with various CAD drugs in a prevalent CAD population. New York: Medical Scientists, Inc., Sep 9, 1999Google Scholar
- 2.Prochaska JO, Redding CO, Evers KE. The transtheoretical model and stages of change. In: Glanz K, Lewis FM, Rimer BK, editors. Health behavior and health education. San Francisco: Jossey-Bass, 1996Google Scholar